

DAINIPPON SUMITOMO– PREVAIL TRIAL DATA: Latuda Will Pave A Way For Bipolar Disorder As Well!

<https://marketpublishers.com/r/DE2AE57B5A1EN.html>

Date: April 2012

Pages: 3

Price: US\$ 90.00 (Single User License)

ID: DE2AE57B5A1EN

Abstracts

Top line data from PREVAIL I & II trials announced on 24 April, 2012, show Latuda (lurasidone, already approved for Schizophrenia) meeting statistical significance for efficacy in adjuvant therapy with lithium or valproate and as monotherapy respectively for Bipolar Disorder I. Top line data suggests that safety was found to be consistency in all trials and in acceptable range. This report analysis key findings from PREVAIL I & II studies and Latuda positioning in bi-polar disorder space.

Contents

COMPANIES MENTIONED

DAINIPPON SUMITOMO

I would like to order

Product name: DAINIPPON SUMITOMO– PREVAIL TRIAL DATA: Latuda Will Pave A Way For Bipolar Disorder As Well!

Product link: <https://marketpublishers.com/r/DE2AE57B5A1EN.html>

Price: US\$ 90.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/DE2AE57B5A1EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

